Ningbo Menovo Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 603538.SS

Ningbo Menovo Pharmaceutical Co., Ltd. Free Cash Flow for the year ending December 31, 2023: USD -29.64 M

Ningbo Menovo Pharmaceutical Co., Ltd. Free Cash Flow is USD -29.64 M for the year ending December 31, 2023, a 30.59% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Ningbo Menovo Pharmaceutical Co., Ltd. Free Cash Flow for the year ending December 31, 2022 was USD -42.70 M, a 12.27% change year over year.
Ningbo Menovo Pharmaceutical Co., Ltd. Free Cash Flow for the year ending December 31, 2021 was USD -48.67 M, a -428.36% change year over year.
Ningbo Menovo Pharmaceutical Co., Ltd. Free Cash Flow for the year ending December 31, 2020 was USD -9.21 M, a 56.75% change year over year.
Ningbo Menovo Pharmaceutical Co., Ltd. Free Cash Flow for the year ending December 31, 2019 was USD -21.30 M, a 42.10% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

Shanghai Stock Exchange: 603538.SS

Ningbo Menovo Pharmaceutical Co., Ltd.

CEO	Mr. Cheng Zhi Yao
IPO Date	April 10, 2017
Location	China
Headquarters	Building1,Ningbo R&D Park
Employees	2,353
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. It offers APIs, intermediates, and formulations for the treatment of cardiovascular, central nervous, respiratory, antitumor, anti-infection, digestive, and geriatric diseases, as well as antiviral. The company was founded in 2004 and is headquartered in Ningbo, China.

Key trends

Past 5 years